BRAF and thyroid cancer: Altered MAPK signaling pathway in many thyroid cancers leads to ERK phosphorylation, proliferation, and invasion hence BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) have been the subject of intense investigation.